Speaker Profile

Ph.D., Executive Vice President & General Director of Microbiome Unit, Ardigen

Dr. Kaja Milanowska-Zabel is a microbiome enthusiast and a bioinformatics researcher. Her personal and professional ambitions led her to exploit the importance of microbiome in human health. In 2016, Kaja joined Ardigen and started research activities in the microbiome space primarily in the area of oncology. In 2018, after becoming one-third of Ardigen’s management board she took over a position of responsibility of the R&D projects. Kaja’s previous professional experience includes the position of assistant professor at the Department of Molecular and Systems Biology, The Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznań, and the Department of Gene Expression at the Institute of Molecular Biology and Biotechnology at the University of Adam Mickiewicz in Poznań. Currently, Kaja is a General Director of a Microbiome Business Unit putting all her powers, passion and belief, that with an in-depth, data-science aid approach we can make a difference by decoding the microbiome to help patients.

Decoding Microbiome with Artificial Intelligence
AI is used in different microbiome research challenges, from signature discovery and time point analysis, to multi-omics, interpretability and more. Thanks to ML methods we are on the path to demystify the complexity of microbiome to unlock the secrets of the data.

 Session Abstract – PMWC 2022 Silicon Valley

Track Chair:
Rita Colwell, Johns Hopkins Bloomberg School of Public Health
Manoj Dadlani, CosmosID

Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.

  • Intro and Overview to Microbiome
    - Rita Colwell, CosmosID
  • Regulatory Perspective
    - Scott Jackson, NIST
  • Metabolomics in Drug Development
    - Rangaprasad Sarangarajan, Metabolon
  • Pharma Drug Development (PANEL)
    Session Chair: Karim Dabbagh, Second Genome
    - Matthew Henn, Seres
    - Rangaprasad Sarangarajan, Metabolon
  • AI in Microbiome
    - Kaja Milanowska-Zabel, Ardigen
  • Direct-To-Consumer Testing/Technologies (PANEL)
    Session Chair: Nathan D. Price, Thorne HealthTech
    - Kiran Krishnan, Microbiome Labs
    - Nicole Scott, Cybele Microbiome
  • Microbiome and Cancer
    - Sandrine Miller-Montgomery, Micronoma
  • The Role of the Human Gut Microbiome on Various Diseases
    - Colleen Cutcliffe, Pendulum Therapeutics
    - Tor Savidge, Baylor College of Medicine
    - Nikole Kimes, Siolta Therapeutics
    - Sarkis Mazmanian, Caltech
  • The Gut/Brain Microbiome
    - Mary Conrad, Axial Biotherapeutics
    - Christopher Reyes, Bloom Science
  • Showcase
    - Heloise Breton, DNA Genotek
    - Nathan Price, Thorne HealthTech
    - Rita Colwell, CosmosID